Merck: to present advances in oncology
(CercleFinance.com) - Merck announces that it will present new data on four approved drugs and six candidates in development for more than 20 types of cancer at the European Society for Medical Oncology (ESMO) 2024 Congress.
Presentations will include Phase 3 studies in triple-negative breast cancer, cervical cancer and unresectable hepatocellular carcinoma.
Merck will also discuss results from its flagship product, Keytruda, as well as other drugs, highlighting progress in clinical research and development of its broad portfolio of oncology treatments.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Presentations will include Phase 3 studies in triple-negative breast cancer, cervical cancer and unresectable hepatocellular carcinoma.
Merck will also discuss results from its flagship product, Keytruda, as well as other drugs, highlighting progress in clinical research and development of its broad portfolio of oncology treatments.
Copyright (c) 2024 CercleFinance.com. All rights reserved.